Skip to main content
Top
Published in: Clinical Research in Cardiology Supplements 1/2015

Open Access 01-04-2015

Extrakardiale Manifestation der Lipoprotein(a)-Erhöhung – Gehäuftes Auftreten von peripherer arterieller Verschlusskrankheit und Stenosen der Arteria carotis

Authors: Dr. Frank van Buuren, MBA, Julia Alexia Sommer, Tanja Kottmann, Dieter Horstkotte, Klaus Peter Mellwig

Published in: Clinical Research in Cardiology Supplements | Special Issue 1/2015

Login to get access

Zusammenfassung

Einleitung

Ein Zusammenhang zwischen erhöhten Lp(a)-Werten und der Inzidenz der KHK ist eindeutig belegt. Die Bedeutung einer Lp(a)-Erhöhung für die Entstehung einer Arteriosklerose mit extrakardialer Manifestation ist bisher nur wenig untersucht. Inwieweit ein erhöhter Lp(a)-Wert als eigenständiger Risikofaktor für das Auftreten einer peripheren arteriellen Verschlusskrankheit (pAVK) und einer Stenose der Arteria carotis interna (ACIS) gesehen werden kann, war Ziel der vorliegenden Untersuchung.

Methodik

In unserer Klinik wurde über 5 Jahre bei 31.734 konsekutiven Patienten ein Lp(a)-Wert bestimmt. Hiervon wurden 1411 Patienten retrospektiv für diese Studie rekrutiert. Die Patienten wurden nach Matching hinsichtlich Alter, Geschlecht und übriger Risikofaktoren in sechs etwa gleich große Gruppen gemäß des erhobenen Lp(a)-Wertes eingeteilt. Wir bestimmten die Häufigkeit einer pAVK und einer ACIS. Keiner der Patienten hatte ein LDL > 130 mg/dl oder ein HbA1c ≥ 6,1 %.

Ergebnisse

In der Gruppe mit Lp(a)-Werten < 2 mg/dl betrug die Häufigkeit einer relevanten pAVK 1,9 % (ACIS 2,8 %), bei Lp(a) 23–29 mg/dl 7,3 % (6,1 %), 30–60 mg/dl 9,0 % (8,3 %), 60–91 mg/dl 11,4 % (7,9 %), 91−110 mg/dl 8,6 % (6,0 %) und > 110 mg/dl 12,7 % (10,9 %).

Zusammenfassung

Es besteht ein Zusammenhang zwischen der Lp(a)-Konzentration und dem Auftreten einer nichtkardialen Arteriosklerose. Bereits Lp(a)-Konzentrationen < 30 mg/dl führen zu einem gehäuften Auftreten sowohl einer pAVK wie auch einer ACIS. Die aktuellen Grenzwertempfehlungen müssen zwingend angepasst werden, da bereits im Vergleich der Gruppen mit niedrig- und hochnormalen Werten deutliche Unterschiede dokumentiert wurden.
Literature
1.
go back to reference Kamstrup PR (2010) Lipoprotein(a) and ischemic heart disease–a causal association? A review. Atherosclerosis 211:15–23CrossRefPubMed Kamstrup PR (2010) Lipoprotein(a) and ischemic heart disease–a causal association? A review. Atherosclerosis 211:15–23CrossRefPubMed
2.
go back to reference Erqou S, Kaptoge S, Perry PL et al, Emerging Risk Factors Collaboration (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302:412–423CrossRefPubMed Erqou S, Kaptoge S, Perry PL et al, Emerging Risk Factors Collaboration (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302:412–423CrossRefPubMed
3.
go back to reference Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG (2013) Extreme lipoprotein (a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 19:1146–1156CrossRef Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG (2013) Extreme lipoprotein (a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 19:1146–1156CrossRef
4.
go back to reference Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, European Atherosclerosis Society Consensus Panel (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:2844–2853CrossRefPubMedCentralPubMed Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, European Atherosclerosis Society Consensus Panel (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31:2844–2853CrossRefPubMedCentralPubMed
5.
go back to reference Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, Collins R, Heart Protection Study Collaborative Group (2011) Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet 4:68–73CrossRefPubMed Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, Collins R, Heart Protection Study Collaborative Group (2011) Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet 4:68–73CrossRefPubMed
6.
go back to reference Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN (2014) Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis 235:477–482CrossRefPubMed Ezhov MV, Safarova MS, Afanasieva OI, Kukharchuk VV, Pokrovsky SN (2014) Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis 235:477–482CrossRefPubMed
7.
go back to reference Laschkolnig A, Kollerits B, Lamina C, Meisinger C, Rantner B, Stadler M, Peters A, Koenig W, Stöckl A, Dähnhardt D, Böger CA, Krämer BK, Fraedrich G, Strauch K, Kronenberg F (2014) Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 103:28–36CrossRefPubMedCentralPubMed Laschkolnig A, Kollerits B, Lamina C, Meisinger C, Rantner B, Stadler M, Peters A, Koenig W, Stöckl A, Dähnhardt D, Böger CA, Krämer BK, Fraedrich G, Strauch K, Kronenberg F (2014) Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 103:28–36CrossRefPubMedCentralPubMed
8.
go back to reference Maca T, Mlekusch W, Doweik L, Budinsky AC, Bischof M, Minar E, Schillinger M (2007) Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease. Eur J Clin Invest 37:180–186CrossRefPubMed Maca T, Mlekusch W, Doweik L, Budinsky AC, Bischof M, Minar E, Schillinger M (2007) Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease. Eur J Clin Invest 37:180–186CrossRefPubMed
9.
go back to reference Prior M, Arosio E, Ferrari M, Lucchese L, Guidi GC, Bosello O (1995) Lipoprotein(a) and general risk factors in patients with angiographically assessed peripheral arterial disease. Int Angiol 14:357–363PubMed Prior M, Arosio E, Ferrari M, Lucchese L, Guidi GC, Bosello O (1995) Lipoprotein(a) and general risk factors in patients with angiographically assessed peripheral arterial disease. Int Angiol 14:357–363PubMed
10.
go back to reference Widmann MD, Sumpio BE (1993) Lipoprotein (a): a risk factor for peripheral vascular disease. Ann Vasc Surg 7:446–451CrossRefPubMed Widmann MD, Sumpio BE (1993) Lipoprotein (a): a risk factor for peripheral vascular disease. Ann Vasc Surg 7:446–451CrossRefPubMed
11.
go back to reference Tyrrell J, Cooke T, Reilly M, Colgan M, Moore D, Shanik DG, Bergin C, Feely J (1992) Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med 232:349–352CrossRefPubMed Tyrrell J, Cooke T, Reilly M, Colgan M, Moore D, Shanik DG, Bergin C, Feely J (1992) Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med 232:349–352CrossRefPubMed
12.
go back to reference Boras J, Ljubic S, Car N, Metelko Z, Petrovecki M, Lovrencic MV, Reiner Z (2010) Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: a four-year follow-up. Wien Klin Wochenschr 122:159–164CrossRefPubMed Boras J, Ljubic S, Car N, Metelko Z, Petrovecki M, Lovrencic MV, Reiner Z (2010) Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: a four-year follow-up. Wien Klin Wochenschr 122:159–164CrossRefPubMed
13.
go back to reference Wollesen F, Dahlén G, Berglund L, Berne C (1999) Peripheral atherosclerosis and serum lipoprotein(a) in diabetes. Diabetes Care 22:93–98CrossRefPubMed Wollesen F, Dahlén G, Berglund L, Berne C (1999) Peripheral atherosclerosis and serum lipoprotein(a) in diabetes. Diabetes Care 22:93–98CrossRefPubMed
14.
go back to reference Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJ, Stampfer MJ, Marcovina SM (2004) Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians’ Health Study. Clin Chem 50:1364–1371CrossRefPubMed Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJ, Stampfer MJ, Marcovina SM (2004) Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians’ Health Study. Clin Chem 50:1364–1371CrossRefPubMed
15.
go back to reference Sommer JA (2015) Die Bedeutung der Lipoprotein (a) Erhöhung für die Entstehung der Arteriosklerose. Dissertation Universität Bochum. Eingereicht 2015 Sommer JA (2015) Die Bedeutung der Lipoprotein (a) Erhöhung für die Entstehung der Arteriosklerose. Dissertation Universität Bochum. Eingereicht 2015
16.
go back to reference Solfrizzi V, Panza F, Colacicco AM, Capurso C, D’Introno A, Torres F, Baldassarre G, Capurso A (2002) Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients > or = 65 years of age (The Italian Longitudinal Study on Aging). Am J Cardiol 89:825–829CrossRefPubMed Solfrizzi V, Panza F, Colacicco AM, Capurso C, D’Introno A, Torres F, Baldassarre G, Capurso A (2002) Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients > or = 65 years of age (The Italian Longitudinal Study on Aging). Am J Cardiol 89:825–829CrossRefPubMed
17.
go back to reference Song P, Seok JM, Kim WS, Lee YT, Kim DK, Kim GM (2011) Increased lipoprotein(a) is associated with polyvascular disease in patients undergoing coronary artery bypass graft. Atherosclerosis 219:285–290CrossRefPubMed Song P, Seok JM, Kim WS, Lee YT, Kim DK, Kim GM (2011) Increased lipoprotein(a) is associated with polyvascular disease in patients undergoing coronary artery bypass graft. Atherosclerosis 219:285–290CrossRefPubMed
18.
go back to reference Bea AM, Mateo-Gallego R, Jarauta E, Villa-Pobo R, Calmarza P, Lamiquiz-Moneo I, Cenarro A, Civeira F (2014) Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia. Clin Investig Arterioscler 26:176–183CrossRefPubMed Bea AM, Mateo-Gallego R, Jarauta E, Villa-Pobo R, Calmarza P, Lamiquiz-Moneo I, Cenarro A, Civeira F (2014) Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia. Clin Investig Arterioscler 26:176–183CrossRefPubMed
19.
go back to reference Ghorbani A, Rafieian-Kopaei M, Nasri H (2013) Lipoprotein (a): more than a bystander in the etiology of hypertension? A study on essential hypertensive patients not yet on treatment. J Nephropathol 2:67–70CrossRefPubMedCentralPubMed Ghorbani A, Rafieian-Kopaei M, Nasri H (2013) Lipoprotein (a): more than a bystander in the etiology of hypertension? A study on essential hypertensive patients not yet on treatment. J Nephropathol 2:67–70CrossRefPubMedCentralPubMed
20.
go back to reference Mellwig KP, van Buuren F, Schmidt HK, Wielepp P, Burchert W, Horstkotte D (2006) Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment. Ther Apher Dial 10:510–517CrossRefPubMed Mellwig KP, van Buuren F, Schmidt HK, Wielepp P, Burchert W, Horstkotte D (2006) Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment. Ther Apher Dial 10:510–517CrossRefPubMed
21.
go back to reference Dionyssiou-Asteriou A, Papastamatiou M, Vatalas I, Bastounis E (2000) Serum Lp(a) lipoprotein levels in patients with atherosclerotic occlusive disease of the lower extremities. Eur J Vasc Endovasc Surg 20:57–60CrossRefPubMed Dionyssiou-Asteriou A, Papastamatiou M, Vatalas I, Bastounis E (2000) Serum Lp(a) lipoprotein levels in patients with atherosclerotic occlusive disease of the lower extremities. Eur J Vasc Endovasc Surg 20:57–60CrossRefPubMed
22.
go back to reference Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481–2485CrossRefPubMed Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481–2485CrossRefPubMed
23.
go back to reference Volpato S, Vigna GB, McDermott MM, Cavalieri M, Maraldi C, Lauretani F, Bandinelli S, Zuliani G, Guralnik JM, Fellin R, Ferrucci L (2010) Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study). Am J Cardiol 105:1825–1830CrossRefPubMedCentralPubMed Volpato S, Vigna GB, McDermott MM, Cavalieri M, Maraldi C, Lauretani F, Bandinelli S, Zuliani G, Guralnik JM, Fellin R, Ferrucci L (2010) Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study). Am J Cardiol 105:1825–1830CrossRefPubMedCentralPubMed
24.
go back to reference Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A (2006) Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 113:2623–2629CrossRefPubMed Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A (2006) Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 113:2623–2629CrossRefPubMed
25.
go back to reference Tselmin S, Julius U, Müller G, Fischer S, Bornstein SR (2009) Cardiovascular events in patients with increased lipoprotein(a) – retrospective data analysis in an outpatient department of lipid disorders. Atherosclerosis Suppl 10:79–84CrossRef Tselmin S, Julius U, Müller G, Fischer S, Bornstein SR (2009) Cardiovascular events in patients with increased lipoprotein(a) – retrospective data analysis in an outpatient department of lipid disorders. Atherosclerosis Suppl 10:79–84CrossRef
26.
go back to reference Rosada A, Kassner U, Vogt A, Wilhauck M, Parhofer K, Steinhagen-Thiessen E (2014) Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artificial Organs 38:135–141CrossRefPubMed Rosada A, Kassner U, Vogt A, Wilhauck M, Parhofer K, Steinhagen-Thiessen E (2014) Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artificial Organs 38:135–141CrossRefPubMed
27.
go back to reference Leebmann J, Roeseler E, Julius U et al, Pro(a) LiFe Study Group (2013) Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128:2567–2576CrossRefPubMed Leebmann J, Roeseler E, Julius U et al, Pro(a) LiFe Study Group (2013) Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 128:2567–2576CrossRefPubMed
28.
go back to reference Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301:2331–2339CrossRefPubMed Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301:2331–2339CrossRefPubMed
29.
go back to reference Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS (2012) Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 32:3058–3065CrossRefPubMedCentralPubMed Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS (2012) Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 32:3058–3065CrossRefPubMedCentralPubMed
30.
go back to reference Li SY, Gao Y, Ma WN, Wang HC, Zhou G, Guo WC, Liu YH (2014) The relationship between serum lipoprotein (a) levels and ischemic stroke risk: a cohort study in the Chinese population. Inflammation 37:686–693CrossRefPubMed Li SY, Gao Y, Ma WN, Wang HC, Zhou G, Guo WC, Liu YH (2014) The relationship between serum lipoprotein (a) levels and ischemic stroke risk: a cohort study in the Chinese population. Inflammation 37:686–693CrossRefPubMed
Metadata
Title
Extrakardiale Manifestation der Lipoprotein(a)-Erhöhung – Gehäuftes Auftreten von peripherer arterieller Verschlusskrankheit und Stenosen der Arteria carotis
Authors
Dr. Frank van Buuren, MBA
Julia Alexia Sommer
Tanja Kottmann
Dieter Horstkotte
Klaus Peter Mellwig
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology Supplements / Issue Special Issue 1/2015
Print ISSN: 1861-0706
Electronic ISSN: 1861-0714
DOI
https://doi.org/10.1007/s11789-015-0069-x

Other articles of this Special Issue 1/2015

Clinical Research in Cardiology Supplements 1/2015 Go to the issue